Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant toripalimab plus gemcitabine and cisplatin for locally advanced upper tract urothelial carcinoma
ChiCTR2500102886Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab, gemcitabine and cisplatin in upper tract urothelial carcinoma (UTUC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Pathological complete response. Started May 2025; status: recruiting.
02
Drugs
toripalimabgemcitabinecisplatin
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on ChiCTR2500102886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102886.